azithromycin
azithromycin: 12 clinical trials tracked.
azithromycin evidence translation
What we can confirm
12 tracked trials
What it means
What to watch
Prepared research question
What is verified about azithromycin, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 3 study sponsors
Clinical Trials (12)showing 10 most recent
Co-SAM: An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated Severe Acute Malnutrition
Primary endpoint: Death or first hospitalisation or failed nutritional recovery within 24 weeks post-randomisation
An Open-Label, Phase 2 Study to Evaluate the Activity of Belumosudil in Subjects With New Onset and Incipient Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell Transplantation
Primary endpoint: 24-week Overall Response Rate (ORR) [Cohort A]
Unlocking New Avenues: Azithromycin Vs Erythromycin in Pre-term, Pre-mature Rupture of Membrane Management
Primary endpoint: Maternal Outcome
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study, Followed by Open-label Extensions, to Evaluate the Efficacy of Oral Belumosudil in Adult Participants With Chronic Lung Allograft Dysfunction (CLAD) Following Bilateral Lung Transplantation
Primary endpoint: Percent change from baseline to Week 26 in forced expiratory volume in 1 second (FEV1)
Improving Cognition and Gestational Duration With Targeted Nutrition
Primary endpoint: Gestational duration
Azithromycin to Prevent Chorioamnionitis in Women Undergoing Induction of Labor, a Randomized Control Trial
Primary endpoint: Change in Composite Infection
Outpatient Antibiotics Following Previable Rupture of Membranes (pPPROM) Between 18 0/7 and 22 6/7 Weeks Gestational Age
Primary endpoint: Delivery Within 28 Days
Azithromycin Prophylaxis in Child Contacts of Cholera Patients: A Randomized Controlled Trial
Primary endpoint: Rate of V. Cholerae Infection in Household Contacts of Cholera Index Cases
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)
Primary endpoint: Change from Baseline in Respiratory Symptom Score at Month 13
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)
Primary endpoint: Psychometric Cross-Sectional Validation of Patient Reported Outcome (PRO): Patient Global Impression of Severity (PGI-S) Respiratory Scale Score at Baseline